
Clene Inc.
CLNN·NASDAQ
Last updated as of 2026-05-11 20:19 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
CLNN stock price change
On the last trading day, CLNN stock closed at 7.49 USD, with a price change of 2.88% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreCLNN key data
Previous close7.49 USD
Market cap88.22M USD
Volume34.12K
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-2.60 USD
Net income (FY)−26.17M USD
Revenue (FY)200.00K USD
Next report dateMay 13, 2026
EPS estimate-
Revenue estimate57.00K USD USD
Shares float8.99M
Beta (1Y)2.61

Clene Inc. overview
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Robert Dee Etherington
Headquarters
Salt Lake City
Website
clene.com
Founded
2013
Employees (FY)
79
Change (1Y)
+3 +3.95%
Revenue / Employee (1Y)
2.53K USD
Net income / Employee (1Y)
−331.30K USD
CLNN stock price forecast
According to technical indicators for CLNN stock, the price is likely to fluctuate within the range of 7.71–8.72 USD over the next week. Market analysts predict that the price of CLNN stock will likely fluctuate within the range of 7.64–10.78 USD over the next months.
Based on 1-year price forecasts from 26 analysts, the highest estimate is 11.14 USD, while the lowest estimate is 6.23 USD.
For more information, please see the
CLNN stock price forecast
page.
Latest CLNN stock news
Clene to Present at the Emerging Growth Conference
Finviz2026-02-19 13:33:13
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts
Finviz2026-02-24 13:03:08
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Finviz2026-03-12 12:06:46
Biopharmaceutical company Clene Inc (CLNN) recently unveiled its new financing strategy—two potential additional financings totaling over $22 millions have completed structural design. This funding plan will enable the company’s operational cash flow to last until 2027.
老虎证券2026-03-12 12:22:48
Clene to Present at the Emerging Growth Conference
Finviz2026-02-19 13:33:13
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts
Finviz2026-02-24 13:03:08
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Finviz2026-03-12 12:06:46
Biopharmaceutical company Clene Inc (CLNN) recently unveiled its new financing strategy—two potential additional financings totaling over $22 millions have completed structural design. This funding plan will enable the company’s operational cash flow to last until 2027.
老虎证券2026-03-12 12:22:48





